profit from every $100 of sales.
$0$100
Waystar
$29.30+0.41% today
-18.0% in 1 year
1-year low $17.311-year high $37.04
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $50.29 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Waystar sold, what it kept, and what it did with the cash.
Sales went from $705 million in 2022 to $1.10 billion in 2025, with $112 million of profit last year.
SalesProfit
Waystar vs. similar companies
Waystar grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Waystar | 50.3× · Expensive | ||
 Veeva Systems | 54.4× · Expensive | ||
 Pro Medicus | 186.7× · Very expensive | ||
 Hinge Health | No profit yet | ||
 M3 | 31.0× · Expensive |
AI analysis
An AI analyst reads Waystar's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 705 | 791 | 944 | 1,099 | |
| 490 | 541 | 628 | 751 | |
| 89 | 142 | 124 | 249 | |
| 273 | 319 | 310 | 390 | |
| -51 | -51 | -19 | 112 | |
| -0.31 | -0.31 | -0.13 | 0.61 | |
| 69.5% | 68.4% | 66.5% | 68.3% | |
| 12.7% | 18.0% | 13.1% | 22.7% | |
| -7.3% | -6.5% | -2.0% | 10.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,694 | 4,583 | 4,577 | 5,785 |
| Cash | 65 | 36 | 182 | 61 |
| Total debt | 2,261 | 2,249 | 1,263 | 1,491 |
| Total liabilities | 2,588 | 2,533 | 1,497 | 1,906 |
| 2,106 | 2,050 | 3,080 | 3,879 | |
| 167 | 167 | 150 | 185 | |
| 1.6% | 2.6% | 2.3% | 3.7% | |
| -2.4% | -2.5% | -0.6% | 2.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 103 | 51 | 170 | 310 | |
| 17 | 22 | 27 | 26 | |
| 85 | 30 | 143 | 283 | |
| Dividends paid | – | – | – | – |
| 2 | 1 | 1 | 0 | |
| 8 | 9 | 54 | 42 |
Valuation
- 50.3×
- 17.9×
- –
- 1.4×
- 5.1×
- 19.9×
- 18.1×
- 5.0%
- 2.0%
- 0.0%
Profitability
- 68.3%
- 22.7%
- 10.2%
- 37.1%
- 3.8%
- 2.6%
- 3.5%
- 2.2%
- 5.0%
- 5.4%
Growth
- +16.0%
- –
- +98.7%
- –
- +3.5%
Financial health
- 3.7×
- 0.38
- 0.5%
- 3.2×
- 1.41
- 1.76
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 45%of 945
Top 19%of 870
Bottom 22%of 559
Top 37%of 867
Top 21%of 986
What analysts expect
- Average price target
- $35.62
- Range
- $27.00 – $43.00
- 12 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.42 | 0.39 | +7.7% |
| Feb 17, 2026 | 0.36 | 0.39 | −7.7% |
| Oct 29, 2025 | 0.37 | 0.34 | +8.8% |
| Jul 30, 2025 | 0.36 | 0.33 | +9.1% |
| Apr 30, 2025 | 0.32 | 0.32 | +0.0% |
| Feb 18, 2025 | 0.29 | 0.15 | +93.3% |
| Nov 6, 2024 | 0.14 | 0.11 | +27.3% |
| Aug 7, 2024 | 0.04 | 0.01 | +325.1% |
News
Paramount Resources raised at Scotiabank as Kaybob sale clears way for next leg of growthSeeking Alpha · Nov 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
35No pass
Philip Fisher
45No pass
Peter Lynch
70Pass
Joel Greenblatt
5No pass
Charlie Munger
32No pass
Terry Smith
40No pass
Questions about Waystar
Is Waystar a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Waystar AI analysis
What does Waystar do?
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. It is in Health Information Services, based in Lehi, UT, United States, with 1,700 employees.
Does Waystar pay a dividend?
No. Waystar does not pay a dividend at the moment.
Is Waystar stock halal?
Yes. Waystar passes our halal screen: its business is permitted and its debt is 27% of its market value, under the 30% limit. How we check
How has Waystar stock done over the past year?
Down 18.0% over the past twelve months, to $29.30. It traded between $17.31 and $37.04 and is 20.9% below its high.
Who are Waystar's competitors?
The largest listed companies in the same industry are Veeva Systems, Pro Medicus, Hinge Health and M3. The peers table on this page compares their profit, growth and price with Waystar's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.